Biogen Inc. (BIIB)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 10:48AM EST. Market open.
| Previous close | 288.28 |
| Open | 286.50 |
| Bid | 286.79 x 800 |
| Ask | 287.00 x 2200 |
| Day's range | 285.10 - 289.63 |
| 52-week range | 187.16 - 311.88 |
| Volume | |
| Avg. volume | 1,196,970 |
| Market cap | 41.312B |
| Beta (5Y monthly) | 0.21 |
| PE ratio (TTM) | 14.62 |
| EPS (TTM) | 19.62 |
| Earnings date | 15 Feb 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 322.26 |
- Simply Wall St.
Is Biogen Inc. (NASDAQ:BIIB) Trading At A 24% Discount?
How far off is Biogen Inc. ( NASDAQ:BIIB ) from its intrinsic value? Using the most recent financial data, we'll take a...
- Zacks
Biogen Inc. (BIIB) Gains As Market Dips: What You Should Know
Biogen Inc. (BIIB) closed at $288.28 in the latest trading session, marking a +1.64% move from the prior day.
- Business Wire
Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
CAMBRIDGE, Mass., February 06, 2023--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced the U.S. Food and Drug Administration (FDA) has accepted the filing of a New Drug Application (NDA) for zuranolone in the treatment of major depressive disorder (MDD) and postpartum depression (PPD). Zuranolone is an investigational drug being evaluated as a 14-day, rapid-acting, once-daily, oral treatment in adults with MDD and PPD. The application has been granted priority revie
© 2023 Yahoo. All rights reserved.
